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Background/Aims
Eosinophilic esophagitis (EoE) is a chronic inflammatory disorder of the esophagus. Similar to asthma, EoE can induce irrever-
sible structural changes in the esophagus as a result of chronic and persistent eosinophilic inflammation. The aim of this study 
was to analyse changes in symptoms, eosinophil counts and endoscopic findings after treatment. 
Methods
Nine patients with EoE (6 men and 3 women; mean age, 36.44 years) were diagnosed with EoE based on typical symptoms, 
endoscopic abnormalities and infiltration of the esophageal epithelium with ≥ 15 eosinophils/high-power field. The average 
endoscopic follow-up period was 10 months, ranging from 1 to 25 months. Symptoms and endoscopic and pathological find-
ings at initial observation and follow-up were evaluated. 
Results
Seven of the 9 patients had dysphagia symptoms, which improved in 4 of 6 patients who were treated with proton pump 
inhibitor. Two patients were unresponsive to proton pump inhibitor and another 2 patients were treated with corticosteroid, 
which led to symptomatic relief. In 8 patients, esophageal eosinophilia was improved histologically at follow-up after 
treatment. Six of the 9 patients had typical endoscopic findings of EoE at initial examination. Despite treatment, these findings 
remained in 5 of the 6 patients at follow-up endoscopy. 
Conclusions
After treatment, the symptoms and eosinophil counts were temporarily improved, but the endoscopic findings of EoE were 
generally not improved. This indicates that deformity of esophageal structure due to eosinophilic inflammation might be irre-
versible despite proper management.
(J Neurogastroenterol Motil 2013;19:204-209)
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Introduction
Primary eosinophilic esophagitis (EoE) is a chronic in-
flammatory disorder associated with eosinophilic infiltration of 
the esophagus. The first case was described by Landres et al1 
more than 30 years ago, and in 1993 Attwood et al2 reported the 
first study of 12 adult patients with esophageal eosinophilia with 
dysphagia. Recently, EoE has been increasingly recognized and 
actively investigated in Western countries. However, in Asian 
populations there are very few reported adult cases of EoE and 
only limited studies have been performed. In our hospital, EoE 
has been actively studied and clinical implications3 and clin-
icopathological features4 have been reported.
In adults, EoE is predominantly observed in male patients 
and the average age of onset is between the twenties and forties. 
Dysphagia with solid food impaction is the most common symp-
tom in adult patients with EoE. Heartburn or chest pain has also 
been reported.5,6 In some cases typical symptoms persist despite 
prolonged treatment with proton pump inhibitor (PPI) or normal 
pH monitoring of the distal esophagus.7,8 EoE with typical symp-
toms and endoscopic findings is confirmed by a high degree of esoph-
ageal eosinophilic infiltration (≥ 15/high power field [HPF]).8
A recent study from Japan9 reported symptoms, endoscopic 
and pathological findings, and treatment outcomes for 12 pa-
tients with EoE. Seven patients treated with PPI or topical ste-
roid therapy showed symptomatic and histological improvemen-
ts. However, treatment outcomes were not evaluated in 5 patients 
and only 2 patients, who were treated with oral fluticasone propi-
onate as topical steroid therapy, showed improved endoscopic 
findings at follow-up.
Another study10 investigated the natural history of 30 adult 
patients with EoE during a mean 7.2-year follow-up period and 
reported that endoscopic findings were not significantly changed 
at follow-up. Esophageal eosinophilic infiltration persisted in all 
symptomatic patients, but cell numbers decreased significantly. 
The authors suggested that chronic inflammation may lead to ir-
reversible structural changes in the esophagus with a concomitant 
risk of impaired function.
Despite an increased understanding of inflammatory patho-
genesis and possible irreversible structural changes in the esoph-
agus, changes in endoscopic findings following treatment of EoE 
are not clearly defined. The aim of our study was to analyze 
changes in symptoms, eosinophil counts, and endoscopic find-
ings after treatment in patients with EoE.
Materials and Methods
We reviewed patients with clinically, endoscopically, and his-
tologically confirmed diagnoses of EoE, retrospectively. The di-
agnostic confirmation for EoE was defined as a peak of ≥ 15 eo-
sinophils/HPF. Among patients with confirmed EoE, those who 
did not undergo endoscopic examination at follow-up were 
excluded. Consequently, 9 patients with EoE, who were diag-
nosed at 4 university hospitals between June 2006 and December 
2011, were included. Before proceeding the study, we obtained 
the permission from the Institutional Review Board of Gangnam 
Severance Hospital, Yonsei University College of Medicine.
We considered baseline characteristics of sex, age, and body 
mass index (BMI). Allergic history included food allergy, aller-
gic rhinitis, allergic dermatitis and asthma. Serum haematologic 
and chemistry sampling was performed and analysed. 
Analysed symptoms were dysphagia, heartburn, chest pain, 
and sore throat. We assessed dysphagia intensity using the fol-
lowing scoring system10:1 = swallowing unhindered and without 
pain, 2 = slight retching disappearing spontaneously (sponta-
neous anterograde removal), 3 = short periods of obstruction ne-
cessitating intervention such as drinking, deep breathing or 
retching (induced anterograde removal), 4 = longer-lasting ob-
struction only removable by vomiting (forced retrograde re-
moval) and 5 = continuous complete obstruction not removable 
by the patient (requiring endoscopic intervention). 
We performed endoscopic examinations at first examination 
and follow-up. Typical findings were linear furrow, corrugated 
ring, stricture, friability, and white plaque. Endoscopic findings 
were classified using the following scoring system10: 1 = absent, 
2 = minimal (fine nodule or fine whitish reticular structure or 
linear furrow), 3 = moderate (bright-whitish scale-like, pla-
que-like structure or corrugated ring) and 4 = severe (mucosal 
lesion or fixed stenosis). 
Reflux oesophagitis was also confirmed and graded. Endo-
scopic esophageal biopsy specimens were obtained from mid or 
lower esophagus of all patients, regardless of their symptoms and 
endoscopic findings. Tissue samples from endoscopic biopsy 
were analysed for eosinophil counts and other histologic findings 
at first examination and follow-up.
Treatment for EoE was PPI and/or inhaled or oral cortico-
steroid (fluticasone propionate) for 4-8 weeks. The treatment re-
sponses of pathologic condition (eosinophilic counts) were classi-
fied by the following degree of the result: persistence = ≥ 
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Table 2. Follow-up Results of Endoscopic and Histologic Findings, Dysphagia Score, Reflux Esophagitis and Treatment Outcomes
Case 
No.
Initial Interval of 
follow-up 
endoscopy 
(mo)
Treatment outcomes
Endoscopic 
finding
Dysphagia 
score
Reflux 
esophagitis
Therapeutic 
agent
Esophageal 
eosinophilia
Endoscopic alteration
Dysphagia 
score
Reflux 
esophagitis
1 Linear furrow 
Concentric rings
3 (−) 3 PPI Disappearance No change 1 (−)
2 Linear furrow 
Concentric rings
1 (＋) 3 PPI Disappearance No change 1 (−)
3 Linear furrow 2 (−) 6 PPI Disappearance Aggravation 
(white plaque)
2 (−)
4 Linear furrow 3 (−) 6 No treatment Disappearance Partial improvement 1 (−)
5 Linear furrow 
Concentric rings
2 (−) 25 PPI (first)
Oral steroid (second)
Disappearance No change 1 (−)
6 Normal 4 (＋) 1 Oral steroid Disappearance Normal 1 (−)
7 Linear furrow 
Concentric rings
1 (−) 21 Oral steroid Disappearance Partial improvement 2 (−)
8 Nodularity 2 (−) 2 PPI Decrease Normal 1 (−)
9 Normal 3 (−) 5 PPI (first)
Oral steroid (second)
Persistence Normal 2 (−)
Dysphagia intensity score: 1 = swallowing unhindered and without pain, 2 = slight retching disappearing spontaneously, 3 = short periods of obstruction necessitating
intervention such as drinking, deep breathing or retching, 4 = longer-lasting obstruction only removable by vomiting and 5 = continuous complete obstruction not 
removable by the patient.
PPI, proton pump inhibitor.
Table 1. Characteristics of Subjects
Case No. Age (yr) Gender Symptom Allergic condition
1 48 M Dysphagia Yes (unknown factor)
2 24 M No symptom Yes (food)
3 19 M Dysphagia
  Sore throat
Asthma
Allergic rhinitis
4 60 M Dysphagia No
5 58 F Dysphagia
  Heartburn
No
6  8 F Dysphagia
  Vomiting
No
7 49 F Sore throat No
8 28 M Dysphagia No
9 34 M Dysphagia Yes (food)
15/HPF, decrease = 4-14/HPF and disappearance = < 4/HPF. 
Results
Nine patients (6 men and 3 women) with EoE that was con-
firmed histologically by endoscopic biopsy were enrolled in this 
study. The age, gender, symptoms, allergic state and dysphagia 
intensity of enrolled patients are summarised in Table 1 and fol-
low-up results of endoscopic and histological findings, dysphagia 
score, concomitant reflux oesophagitis, and treatment outcomes 
are summarized in Table 2. The mean age of patients was 36.4 
years (range 8-60 years). Five of the patients had allergic con-
ditions such as food allergy, allergic rhinitis, or asthma. Among 
the nine patients, dysphagia symptoms were present in 7 (77.7%), 
sore throat in 2 (22.2%) and heartburn in 1 (11.1%). The dys-
phagia intensity score was 4 in 1 patient, 3 in 3, 2 in 3, and 1 
(normal) in 2. The mean duration of follow-up endoscopy was 8 
months (range 1-25 months). Two of 3 patients with dysphagia 
who were treated with PPI alone showed improvement in 
symptoms. Two patients who had not been responsive to PPI and 
other 2 patients (total 4 patients) were treated with corticosteroid, 
which led to symptomatic relief or reduction of eosinophile 
counts. The overall dysphagia intensity increased from one point 
to two points in 1 patient, was persistent and stable in 2, and de-
creased in 6. Concomitant reflux esophagitis was observed in 2 
patients, but was not evident on follow-up endoscopy. In 8 of the 
9 patients, esophageal eosinophilia was histologically improved 
after treatment at follow-up. Their eosinophilic count were be-
came disappeared (＜ 4/HPF) or decreased (＜ 15/HPF). Six 
of the 9 patients had typical endoscopic findings of EoE at initial 
diagnosis. Despite treatment, 5 of the 6 patients still had typical 
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Figure. Endoscopic changes in cases 
No.2 (A, B) and No.5 (C, D). (A) 
Initial endoscopic finding was linear 
furrow, which was maintained at follow-
up endoscopy (after 3 months). (B) 
Eosinophilia disappeared. (C) Initial 
finding was linear furrow pattern, and 
follow-up endoscopy showed a “crepe
paper mucosa” pattern (after 25 months).
(D) Eosinophilia disappeared.
findings at follow-up endoscopy (Figure).
Discussion
EoE is a specific disease associated with limited esophageal 
structure and overt eosinophilic infiltration and has typical symp-
toms of dysphagia or food impaction. In the past, eosinophilic in-
filtration of the esophagus was considered as a pathologic con-
dition of reflux esophagitis.11 However, in 1993 Attwood et al.2 
reported that EoE was distinct from reflux esophagitis and a sep-
arate clinical and pathological condition. EoE is known to be re-
lated to allergic conditions; although EoE is a rare disease, its in-
cidence is increased in patients with certain allergic diseases.12,13
Asthma is a respiratory disease of bronchial structures with 
eosinophilic infiltration and inflammation similar to that in EoE. 
Asthma is a reversible disease in the acute stage, but a chronic 
clinical course can induce irreversible structural changes in the 
bronchus. This so-called ‘remodelling’ can include subepithelial 
fibrosis and angiogenesis, leading finally to loss of function.14
Murine and translational studies support a role for eosino-
phils in the development of structural abnormalities observed in 
the esophageal mucosa.15 In patients with EoE, histologic analy-
sis of the esophagus revealed increased fibrous tissue with thick-
ening and alterations in the subepithelial compartments.6 This 
observation was supported by several later studies that also de-
tected oesophageal fibrosis in the subepithelial layer. For exam-
ple, Aceves et al16 reported subepithelial structural alterations in 
the esophagus of children with EoE. Specifically, they found 
esophageal mucosa with significantly increased fibrosis, vascu-
larity, and vascular activation in the subepithelial compartment of 
all EoE patients. These alterations were not observed in patients 
who had reflux esophagitis. In contrast to patients with reflux 
esophagitis and normal controls, children who had EoE demon-
strated increased expression of transforming growth factor beta 1 
(TGF-β1) in their esophageal mucosa. TGF-β1 plays a crucial 
role in the irreversible inflammatory process and an increase in 
TGF-β1 expression induces development of remodelling signs.17
In our study, baseline values for average age, male/female ra-
tio and personal history of allergic disease were comparable to 
those in other studies. However, our study had no severe pro-
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gressive cases, such as complete obstruction or long segment 
obstruction. 
Our treatment of EoE involved PPI and/or oral or inhaled 
corticosteroid. In the previous studies, the goal of the treatment in 
EoE had not been defined precisely. That is, both symptomatic 
relief and resolution of inflammation by eosinophils were in-
cluded as successful treatment outcomes.18 The study on treat-
ment of EoE is still at the stage of clinical trials. Equally, we also 
did not define the final goal of the treatment in this study. 
Nonetheless, all patients treated with PPI or corticosteroid 
showed effective symptom relief, even though some cases re-
lapsed at long term follow-up. In the patients of EoE, PPI treat-
ment is controversial. Typical EoE is defined as ‘by the un-
responsiveness to PPI.’ However, recent study in Japan dis-
covered the PPI-effective EoE. In this study, out of 9 patients 
who had been on medical care, 5 patients were treated with PPI.9 
The researcher led to a conclusion that EoE which is strictly de-
fined as unresponsiveness to PPI might be rare in Japan. 
Moreover, other studies suggest that PPI treatment was effective 
in EoE patients with confirmed acid-suppression. The ther-
apeutic effect of PPI was suggested to involve attenuation of the 
permeability of the esophageal wall to exogenous allergens and 
curing of mucosal injury through acid suppression, in addition to 
an anti-inflammatory effect.19,20 On the other hand, we cannot ex-
clude the possibility that the PPI-effectiveness is due to the 
GERD combined with EoE. The pathologic relationship or 
overlap between EoE and GERD is yet unclear.21 And like in 
other studies, 2 patients had the reflux esophagitis in our study.22 
We scored dysphagia according to its intensity. Except for 
the child, all patients had a dysphagia intensity score below 3 and 
there was no food impaction. After treatment, the dysphagia 
symptom was generally improved, but some patients showed re-
currence, and some had continued dysphagia symptoms although 
the eosinophil infiltration was greatly reduced. Endoscopic find-
ings of EoE persisted at follow-up despite treatment. The re-
currence and persistence of dysphagia symptoms could be related 
to the typical endoscopic findings at follow-up, which indicate 
that irreversible structural changes were induced in response to 
chronic inflammation due to eosinophil infiltration. Such irrever-
sible structural changes in the esophagus are known to develop in 
typical eosinophil-induced inflammatory processes such as the 
‘asthma remodelling pattern.’ 
There are some limitations in our study. Although it involved 
4 medical centers, it included only a small number of cases and 
the interval time of follow-up endoscopy was not consistent. The 
method and duration of treatment varied from patient to patient. 
For example, some patients were treated with PPI, and the dura-
tion varied from 4 to 8 weeks. Some were treated with steroid, 
and the duration also varied from 6 weeks to 7 months. There-
fore, a large-scale and prospective study is necessary for vali-
dation of the findings of this study.
In summary, our results indicate that treatment of EoE with 
PPI and/or steroids can improve the symptoms and eosinophil 
counts, but endoscopic findings typically persisted at follow-up. 
These results suggest that EoE is a chronic inflammatory disease 
with frequent recurrence and must be managed over a long time 
despite proper treatment. 
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